Results 241 to 250 of about 1,911,537 (311)

Topological Quantum Biomaterials Enable Pyroptosis‐Senescence Coupling for Enhanced Colorectal Cancer Therapy

open access: yesAdvanced Science, EarlyView.
This work reports conceptually unprecedented topological quantum biomaterials derived from engineered Pd3Sn nanostrips for oncological applications. Their near‐Fermi‐level electronic architecture and superior interfacial charge transport facilitate ultrasound‐amplified redox reactions and efficient ROS generation.
Zilu Chen   +10 more
wiley   +1 more source

Targeting the chemokine receptor CXCR4 for cancer therapies. [PDF]

open access: yesBiomark Res
Rueda A   +4 more
europepmc   +1 more source

Disentangling Heterogeneous Molecular Networks for Multi‐Omics‐Driven Cancer Driver Discovery

open access: yesAdvanced Science, EarlyView.
DRIVE integrates PPI topology and pan‐cancer multi‐omics profiles through dual‐view graph disentanglement, contrastive representation learning, and joint optimization. Across six PPI networks, DRIVE outperforms ten baselines and remains robust to structural and annotation perturbations.
Xinjing Gong   +8 more
wiley   +1 more source

Inhibition of constitutive activity of the atypical chemokine receptor 3 by the small-molecule inverse agonist VUF16840. [PDF]

open access: yesMol Pharmacol
Bosma R   +14 more
europepmc   +1 more source

AI‐Designed TREM1‐Targeted LYTAC Nanoparticles Reprogram the Neuroimmune Microenvironment in Traumatic Brain Injury

open access: yesAdvanced Science, EarlyView.
AI‐enabled de novo design of a TREM1 binder, integrated into a BBB‐crossing and macrophage‐targeted nanoplatform, enables TREM1 degradation and attenuates neuroinflammation, thereby promoting neuroprotection and tissue repair after traumatic brain injury. ABSTRACT Secondary neuroinflammation drives progressive damage after traumatic brain injury (TBI),
Yimin Huang   +19 more
wiley   +1 more source

Interleukin-7R and chemokine receptor type 7 differentially regulate metabolism in CD4+ and CD8+ T cells. [PDF]

open access: yesImmunohorizons
Morrissey KA   +5 more
europepmc   +1 more source

CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti‐PD‐1 Therapy

open access: yesAdvanced Science, EarlyView.
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang   +15 more
wiley   +1 more source

Single‐Cell Transcriptomic Profiling Identifies B Cell‐Intrinsic Dysregulation of Sphingolipid Biosynthesis and Could Be Improved by Inhibiting UGCG in Primary Immune Thrombocytopenia

open access: yesAdvanced Science, EarlyView.
This study generates the single‐cell atlas of pathogenic B‐cell subset Bc‐5 in ITP. It identifies RUNX3 as a key survival regulator and uncovers sphingolipid‐driven metabolic reprogramming, validating UGCG inhibition as a therapeutic candidate and building a valuable resource for ITP mechanistic and therapeutic exploration.
Dongmei Luo   +10 more
wiley   +1 more source

Antimicrobial therapy combined with C-C chemokine receptor type 2 modulation dampens mycobacteria-aggravated monocyte activation and atherosclerosis. [PDF]

open access: yesFront Cardiovasc Med
Egoavil-Espejo R   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy